Scienmag

JANUARY 13, 2021

To discover these associations, researchers need to compare the genomes of many individuals at millions of genetic locations or markers, and therefore require cost-effective genotyping technologies. A new statistical method, developed […].

Genomics 57

Genomics Genome Genotype Genetics 57

XTalks

JANUARY 21, 2025

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR).

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

DECEMBER 9, 2020

Maximillian Diaz, a biomedical engineering Ph.D. . “However, our findings are certainly supportive of the hypothesis that addressing social determinants of health such as food and housing insecurity might positively benefit patients, particularly as it relates to keeping their medical appointments and improving clinical outcomes.”

Radiology 52

Radiology Biobanking Genotype Medicine 52

pharmaphorum

NOVEMBER 10, 2021

That’s according to a newly published report from the US National Academies of Sciences, Engineering, and Medicine, which calls for a One Health approach that recognises the scale of the challenge, and the interconnectivity of its potential solutions.

Medicine 105

Medicine Genome Genomics Genotype 105

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Drugs 52

Drugs Genotype Medicine Bioavailability 52

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. osteolabs – Germany’s osteolabs GmbH raised €1.6 million in a second financing round.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52